Inside the research

Centene Corporation

CNC Research profile · latest available data

Price overview

$61.82

▼ -0.10 (-0.2%)

52w hi$69.41
52w lo$31.80
Vol3.63M
As of25 Sep 2026

The Verdict

Hold

Our score +0.26

Short+0.38
Medium+0.35
Long-0.14

computed 2026-09-27

Key fundamentals

Centene Corporation

Healthcare · Healthcare Plans

Market cap$30.54B
Enterprise value$19.68B
Forward P/E11.56x
EV / EBITDA4.27x
P / S (ttm)0.17x
Profit margin-2.8%
Return on equity-20.4%
Revenue growth+4.6%
Debt / equity71.08

Layer Breakdown

LayerRawContribution
Fundamental+0.03
Sector+0.08
Technical+0.27
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

United States · www.centene.com

Risk Metrics

Beta vs SPX0.19
Corr SPX0.06
Annual vol52.1%
Annual ret+5.1%
Sharpe0.10
Max DD-66.5%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$54.94
High / Low$70.00 / $40.00
Median$55.00
Analysts17
Strong Buy2
Buy5
Hold12
Sell1
Strong Sell0

Recent rating actions

2026-05-04TD Cowen→ Hold
2026-05-01Wells Fargo→ Equal-Weight
2026-04-29UBS→ Neutral
2026-04-29Truist Securities→ Buy
2026-04-29Oppenheimer→ Outperform
2026-04-29Cantor Fitzgerald→ Overweight

Officers & Board

CEOSarah London since 2022
DirectorKen Burdick since 2022
DirectorChris Coughlin since 2022
DirectorTed Samuels since 2022
DirectorWayne DeVeydt since 2022
DirectorSarah London since 2021
DirectorBill Trubeck since 2020
DirectorJames Dallas since 2020
DirectorLori Robinson since 2019
DirectorJessica Blume since 2018
DirectorOrlando Ayala since 2011
DirectorDick Gephardt since 2006
DirectorFrederick Eppinger since 2006
DirectorTommy Thompson 2005–2022
DirectorJohn Roberts 2004–2022

Material Events

DateEvent8-K
2026-07-29Other Material Eventread
2026-07-28Earnings Release, Officer / Director Change…read
2026-06-22Officer / Director Change, Reg FD Disclosure…read
2026-05-15Officer / Director Change, Shareholder Voteread
2026-04-28Earnings Release, Exhibitsread
2026-03-24Officer / Director Changeread
2026-03-10Reg FD Disclosure, Other Material Eventread
2026-02-23Reg FD Disclosureread
2026-02-06Earnings Release, Exhibitsread
2025-11-10Reg FD Disclosureread
2025-10-29Earnings Release, Exhibitsread
2025-09-11Reg FD Disclosureread

Insider Trades

DateInsiderRoleActionSharesValue
2026-07-28DIAZ PAUL JGrant2.77K—
2026-07-17Tyler Lauren MGrant3.15K—
2026-06-30Tyler Lauren MGrant61—
2026-06-30TANJI KENNETHGrant581—
2026-06-30Samuels Theodore R. IIGrant465—
2026-06-30EPPINGER FREDERICK HGrant833—
2026-06-30COUGHLIN CHRISTOPHER JGrant562—
2026-06-15SMITH SUSAN RAYEChief Operating OfficerWithheld for tax483$31.49K
2026-06-10Burdick Kenneth ASell80.00K$5.16M

Flow & Concentration

Insider 180d net-$5.16M
Insider buys / sells0 / 1
Insider biasSellers
13F holders0
Top-5 share0.0%
HHI0 (—)

SEC Filings

DateFormDoc
2026-07-298-Kview
2026-07-284view
2026-07-283view
2026-07-2810-Qview
2026-07-288-Kview
2026-07-204view
2026-07-014view
2026-07-014view
2026-07-014view
2026-07-014view
2026-07-014view
2026-06-223view
2026-06-228-Kview
2026-06-154view
2026-06-114view

The Long Run

FY 2010–2025 · 16 years

LineLatestCAGRTrend
Revenue$174.58B+27.7%
Gross profit$17.07B+0.4%
Operating income$3.17B+23.2%
Net income$2.70B+28.2%
Cash from ops$8.05B+27.1%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$62.09$63.67$61.73$61.823.63M
Sep 24$62.16$62.84$61.25$61.924.57M
Sep 23$63.29$63.67$61.87$62.083.42M
Sep 22$64.88$65.30$62.48$63.306.10M
Sep 21$65.19$65.58$64.56$64.994.42M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →